QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conducted by Kernel, a leader in noninvasive neuroimaging. Titled “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” the study was published in “Scientific Reports from the Nature Portfolio of Journals” and evaluated the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. According to the announcement, the single-blind, placebo-controlled…